Dr Sin Yong · MBBS (NUS) · MRCS (Edin) · MSc Aesthetic Medicine (London) · MSc Practical Dermatology (Cardiff) · International KOL
GLP-1 medications — Wegovy (semaglutide), Mounjaro (tirzepatide), Saxenda (liraglutide) — have changed what medicine can offer for weight. They are also prescription-only medicines in Singapore: you qualify for them through a medical assessment, you are titrated and monitored through them, and you are told honestly what they do not fix. This page explains the class; suitability is a consultation decision.
Appetite, satiety and weight defence are hormonally regulated — which is why diets fail so predictably and why the arrival of GLP-1 receptor agonists matters. These medications work with the body’s own appetite signalling rather than against it. That is genuinely new. What has not changed: they are serious prescription medicines, with real side effects, real eligibility criteria and real consequences when used casually or bought from unregulated sources.
In Singapore these are prescription-only medicines regulated by HSA — they cannot be sold to you on request, and any channel offering them without assessment should worry you. Here the sequence is medical: history, examination and metabolic screening first; an eligibility decision against established criteria; then a supervised programme — dose titration, side-effect management, nutrition and muscle preservation, and a maintenance plan for the day the medication stops.
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals satiety to the brain, slows gastric emptying and supports insulin regulation. GLP-1 receptor agonist medications amplify this signalling: appetite quietens, portions shrink naturally, and the constant food-noise many patients describe goes quiet. Semaglutide (Wegovy — weekly injection) and liraglutide (Saxenda — daily injection) work on this receptor; tirzepatide (Mounjaro — weekly) adds a second incretin pathway, GIP, alongside GLP-1.
The honest physiology cuts both ways. Weight lost this way includes muscle unless protein intake and resistance work are planned — one reason unsupervised use ages people. Rapid facial volume loss is real enough to have a nickname (“Ozempic face”), and appetite returns when the medication stops, which is why an exit and maintenance plan belongs in the programme from day one — not improvised at the end. These are management decisions, and they are the difference between a prescription and a programme.
These medicines are indicated for defined BMI thresholds, adjusted for comorbidities — an eligibility decision made at medical assessment, not a lifestyle purchase. If you do not qualify, you will be told, and told why.
Wegovy — semaglutide, weekly. Saxenda — liraglutide, daily. Mounjaro — tirzepatide, weekly, acting on GLP-1 and GIP receptors. Which suits you, if any, depends on your history, goals and response — not on which name you searched.
Nausea, reflux and constipation are common early and usually managed with titration. Gallbladder issues and pancreatitis are recognised, less common risks. This is exactly why supervision and a real medical history matter.
A meaningful share of unsupervised GLP-1 weight loss is muscle. Protein targets, resistance training and body-composition tracking are built into the programme so what you lose is what you meant to lose.
Rapid loss deflates structural facial fat — the “Ozempic face” pattern. Planning for it belongs in the programme; restoring it afterwards is its own discipline — see volume restoration and collagen biostimulators.
Medication changes mass, not architecture. Residual pockets and laxity are addressed separately — fat freezing, body contouring — once weight is stable.
“A prescription medicine is not a shortcut you buy. It is a treatment you qualify for and are supervised through.”Dr Sin Yong
Reference: Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
History, examination, metabolic screening and body composition. Eligibility for prescription therapy is decided against established criteria — and alternatives are discussed if medication is not appropriate.
If indicated, therapy starts low and is titrated stepwise, which is how early side effects are kept manageable. You know what to expect before the first dose.
Regular reviews track weight, body composition, side effects and nutrition. Protein and resistance-training targets protect muscle while the scale moves.
Appetite physiology returns when medication stops — so the maintenance strategy, and any facial or body contour planning, is built before that day, not after it.
They contain the same molecule — semaglutide. Ozempic is registered for type 2 diabetes; Wegovy is the formulation registered for weight management, with its own dosing schedule. Which, if either, is appropriate is a prescribing decision made on your medical picture.
They work differently: Wegovy acts on the GLP-1 receptor; Mounjaro acts on GLP-1 and GIP receptors. Published trials exist for both, but “better” is individual — response, tolerability, medical history and availability all matter, and that is what the assessment weighs. No honest clinic answers this question before examining you.
These are prescription-only medicines indicated at defined BMI thresholds, with lower thresholds when weight-related conditions are present. Eligibility is confirmed at medical assessment — and pursuing them below criteria, or through unregulated online sellers, carries real risk.
Gastro-intestinal effects — nausea, reflux, constipation — are common early and usually settle with careful titration. Gallbladder disease and pancreatitis are recognised, less common risks, and muscle loss is a practical concern the programme actively manages. A full discussion of risks against your history happens before any prescription.
Appetite signalling returns when the medication stops, and regain is common without a maintenance plan — that is physiology, not failure. This is why the exit strategy, habits and monitoring are part of the programme from the start.
Rapid weight loss deflates the structural fat that supports the face, which can read as sudden ageing. Slower, supervised loss with muscle preservation reduces it; where volume loss has already happened, restoration is planned by anatomy afterwards.
Not legally in Singapore without a prescription — and medicines from unregulated sources carry counterfeit and safety risks that are well documented. If a website will sell it to you without a doctor, that is the warning sign.
Prescription medicine pricing is not advertised. Cost depends on the medication, dose and programme structure, and is set out transparently at consultation.
Start with a message, not an appointment. Describe your concern on WhatsApp and you will get a straightforward reply about whether an assessment makes sense, before you commit to coming in.
WhatsApp +65 8023 7170This page is general information, not a diagnosis. Suitability for any treatment is decided at an in-person medical assessment.